Jiangxi Sino Harbour Technology Limited (“Jiangxi Sino Harbour”), a direct subsidiary of Zhejiang Sino Harbour Bio Technology Limited (“Zhejiang Sino Harbour”), which in turn is an indirect wholly-owned subsidiary of the Group, entered into a technical cooperation framework agreement (the “Framework Agreement”) with the Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region (“Guangxi M&C Hospital”) and Zhejiang Gene Stem Cell Biotech Company Limited (“Zhejiang GSCB “) on 28 October 2016. The Framework Agreement stipulates that Jiangxi Sino Harbour and Zhejiang GSCB will establish a joint venture company, which will partner with Guangxi M&C Hospital. Guangxi M&C Hospital will leverage on its own resources and technical advantages to develop stem cell technologies, and the joint venture company has a preferential right to be involved in such technologies developed by Guangxi M&C Hospital. The parties are targeting to build Guangxi M&C Hospital into a leading international stem cell base.

Guangxi Gangrun has a registered capital of RMB10 million. The business activities of Guangxi Gangrun include but are not limited to (i) the storage of biological resources; (ii) genetic testing technology services; (iii) development, transfer and consultation services of cell and genetic products; (iv) development of transgenic biotechnology products, cell culture reagents, biological tissue products, biological diagnostic testing reagents and related consumables; (v) development of other biological products and medical equipment as well as (vi) production and sale of cell products, cell extract, cell culture reagents and diagnostic reagents.


The Group formally commenced stem cell storage business at Guangxi M&C Hospital as its first business development foothold in June 2017.


In December 2017, Guangxi Gangrun entered into a stem cell technical cooperation agreement with the Second Affiliated Hospital of Guilin Medical University (Lingui Clinical Medical College). Both parties will leverage on their respective expertise and resources to carry out perinatal stem cells storage and stem cells technical research projects.


With a substantial increase in national income and public health awareness, the launch of the second child policy and the ageing population, the demand for high-end biomedical services in the PRC will further grow explosively. We firmly believe that the stem cell industry will become one of the pillar industries in the PRC supporting economic growth in the future, and the Group’s high-end pharmaceutical services including pharmaceutical inspection and stem cell will be a driving force for its business development.